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 Corneal endothelial cells do not normally proliferate in
vivo to increase cell numbers. However, they retain prolifera-
tive capacity and can divide both in culture and in ex vivo
corneas if cell-cell contacts are disrupted and cells are exposed
to positive growth factors [1,2]. Epidermal growth factor (EGF)
has been shown to induce proliferation in corneal endothelial
cells from several species, including rabbits [3], cows [4,5],
cats [6,7], non-human primates [8,9], and humans [8,10-12].
Although EGF is known to stimulate proliferation in these
cells, there is very little information regarding how the EGF-
induced signal is regulated.
The EGF receptor (EGFR) is an 1,186 amino acid trans-
membrane protein and is a member of a group of receptors
possessing intrinsic tyrosine kinase activity [13]. Reversible
tyrosine phosphorylation helps regulate important cellular pro-
cesses, including proliferation, migration, and differentiation
[14]. In response to ligand binding, specific tyrosine residues
within the COOH-terminal intracellular domain of EGFR be-
come autophosphorylated. These residues include Tyr992 and
Tyr1148 [15]. Tyrosine autophosphorylation within growth
factor receptors promotes direct binding of signaling proteins
that contain src homology-2 (SH2) domains [15-18]. Ligand
binding to EGFR can lead to activation of a number of signal-
ing pathways, including phospholipase C-γ (PLC-γ) and its
downstream calcium- and protein kinase C (PKC) cascades,
and ras which leads to activation of various MAP kinases.
Upon ligand binding and activation, EGFR is rapidly inter-
nalized into endosomes, with its extracellular domain within
the endosome and its intracellular domain extending toward
the cytoplasm. EGFR remains active in the endosome for sev-
eral min before either being sorted to lysosomes (where it is
degraded) or recycled back to the plasma membrane [19]. The
fate of the receptor and the output of the signaling process
depend on continued ligand binding and kinase activity [13,20].
The catalytic activity of many receptor tyrosine kinases
is tightly regulated by protein tyrosine phosphatases (PTPs),
which act as “on” and “off” switches for numerous signaling
events [14,21]. PTP1B is a widely expressed 50 kDa non-re-
ceptor PTP [22] that helps regulate multiple cellular functions,
including proliferation. Among its functions, PTP1B binds to
the EGFR both in vitro [15] and in vivo [23] and specifically
interacts with and dephosphorylates both Tyr992 and Tyr1148
within the cytoplasmic domain of the receptor [15]. Studies
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indicate that there is competition for PTP1B binding at these
sites. For example, the SH2 domain-containing protein, PLC-
γ, also interacts with Tyr992, while the GTPase-activating pro-
tein of ras (GAP) interacts with Tyr1148. This competitive
binding indicates that PTP1B must play a role in regulating
EGFR downstream signaling via PLC-γ and/or GAP. PTP1B
contains a 35 amino acid COOH-terminal hydrophobic se-
quence that anchors it to the cytoplasmic surface of the endo-
plasmic reticulum [24]. PTP1B-catalyzed dephosphorylation
of EGFR and attenuation of the phosphotyrosine-induced
downstream signal requires receptor endocytosis and occurs
in a specific “dephosphorylation compartment” prior to the
movement of the receptor to lysosomes or to recycling back
to the plasma membrane [14,25,26].
A number of studies have been conducted to determine
whether manipulating the expression or activity of PTP1B can
have an effect on growth factor-induced downstream cellular
processes. For example, PTP1B attenuated PDGF-BB-induced
proliferation in cultured vascular smooth muscle cells via de-
phosphorylation of the PDGF-beta receptor, whereas expres-
sion of a dominant-negative form of PTP1B promoted prolif-
eration of these cells [27]. In immortalized fibroblasts from
PTP1B-/- mice, cells lacking PTP1B exhibited increased and
sustained phosphorylation of both EGFR and the PDGF re-
ceptor [28]. PTP1B also negatively regulates phosphotyrosine-
induced signaling via the insulin and leptin receptors, impli-
cating PTP1B activity in Type 2 diabetes and obesity [29-31].
Because of the potential role of PTP1B in these diseases, as
well as in cancer, much attention has been paid to the devel-
opment of specific inhibitors of PTP1B as potential therapeu-
tic agents [14,32,33].
Studies from this laboratory [34] have demonstrated the
expression of several PTPs in rat corneal endothelial cells both
in ex vivo corneas and in culture. Among the PTPs expressed
were PTP1B, SHP-1, SHP-2, PTP-mu, and the dual-specific-
ity phosphatase, PTEN. When cultures of rat corneal endot-
helial cells were treated with the general phosphatase inhibi-
tor, sodium orthovanadate (SOV), cell cycle entry was in-
creased, as indicated by an increase in the number of cells
with positive staining for Ki67, a marker of actively cycling
cells [35]. The increase in Ki67-positive cells upon exposure
to SOV strongly suggests that phosphatase activity helps sup-
press cell cycle entry in corneal endothelium. The current stud-
ies were conducted to determine whether PTP1B plays a role
in regulating Tyr992 phosphorylation of EGFR and cell cycle
entry in rat corneal endothelial cells.
METHODS
Rat corneal tissue:  Corneas were obtained from adult male
Sprague-Dawley rats (Taconic, Hudson, NY), which were
treated in accordance with the ARVO Statement on the Use of
Animals in Ophthalmic and Vision Research. Whole corneas
were used for some experiments. For other experiments, en-
dothelial cell explant cultures were prepared according to Chen
et al. [36]. Primary cultures were grown to confluence in Me-
dium 199 (Invitrogen, Carlsbad, CA) supplemented with 50
µg/ml gentamicin (Invitrogen) and 10% fetal bovine serum
(FBS; HyClone, Logan, UT). All incubations were performed
at 37 °C in a 5% CO2, humidified atmosphere. Passage 2 cells
were used for all experiments.
RT-PCR of PTP1B:  Total RNA was prepared from pas-
sage 2 subconfluent and confluent cultures of rat corneal en-
dothelial cells according to the manufacturer’s directions
(TRIzol; Invitrogen). cDNA was prepared from 1 µg total RNA
by reverse transcription in a volume of 20 µl using reagents
from a commercially available kit (Promega, Pittsburgh, PA).
Primers specific for PTP1B were available from Santa Cruz
Biotechnology (Santa Cruz, CA). Primer sequences were based
on mouse PTP1B sequences. PCR was performed according
to protocols provided by Santa Cruz and included two PCR
reactions. Briefly, the first PCR reaction was performed in a
mixture containing 100 ng cDNA and 1 µl of Primer Pair A,
plus reagents from a commercially available kit (Qiagen,
Valencia, CA). Specificity and yield of the PCR products were
enhanced using the hot-start approach [37]. PCR was per-
formed for 36 cycles. Cycle conditions included denaturation
at 94 °C for 30 s, annealing at 55 °C for 30 s, and extension at
72 °C for 3 min. A 10 min extension was added at the end of
the 36 cycles of PCR. A second PCR reaction was performed
in a mixture containing 1 µl of product from the first reaction
and 1 µl of Primer Pair B, plus reagents from the aforemen-
tioned commercially available kit. After the hot start, PCR
was performed for 26 cycles, and the conditions were the same
as above except that the extension time at 72 °C was for only
1.5 min. Negative controls consisted of samples containing
all reagents plus primers, but without cDNA. Glyceraldehyde-
3-phosphate dehydrogenase (G3PDH; Clontech, Mountain
View, CA) acted as a positive control for the PCR. To ensure
that the total RNA samples were not contaminated with ge-
nomic DNA, a negative control using 100 ng total RNA was
substituted for cDNA in the PCR reaction mixture, along with
2.5 µM each of upstream and downstream G3PDH primers.
PCR products and 100 bp DNA ladder molecular weight mark-
ers were electrophoresed in 1.5% agarose gels containing 0.5
µg/ml ethidium bromide and photographed. All experiments
were conducted in duplicate and repeated three times to en-
sure consistent results.
Protein extraction and western blot analysis of PTP1B:
Passage 2 subconfluent and confluent cultures of rat corneal
endothelial cells were used for western blot analysis of PTP1B
protein levels. Protein was extracted by incubating cells for
30 min at 4 °C in lysis buffer containing 1% Triton X-100,
250 mM NaCl, 2 mM EDTA, 50 mM Tris-HCl (pH 7.4), 10
µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM
phenylmethylsulfonyl fluoride, 50 mM sodium fluoride, and
0.1 mM sodium orthovanadate (all from Sigma, St. Louis,
MO), followed by sonication and centrifugation. Supernatants
were stored at -80 °C until used for SDS-PAGE and western
blotting. Equal concentrations of soluble protein were loaded
on 10% Bis-Tris gels (Invitrogen) for SDS-PAGE and then
transferred to a polyvinylidene difluoride (PVDF) membrane
(Millipore, Bedford, MA). Nonspecific binding was blocked
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by incubating the membrane overnight at 4 °C in 5% non-fat
dry milk diluted in phosphate-buffered saline (PBS;
Invitrogen). The membrane was incubated for 2 h at room
temperature in PTP1B mouse monoclonal antibody (PH01:
Calbiochem/EMD Biosciences, San Diego, CA) at a concen-
tration of 1.2 mg/ml diluted in 5% non-fat dry milk in PBS.
Blots were then rinsed 2 times for 10 min each with PBS con-
taining 0.1% Triton X-100 and incubated 1 h at room tem-
perature with HRP-conjugated donkey anti-mouse IgG (Jack-
son ImmunoResearch Laboratories, West Grove, PA) diluted
at 1:10,000 in 5% non-fat dry milk in PBS. Membranes were
washed 2 times for 10 min with PBS containing 0.1% Triton
X-100. Antibody binding was visualized using a chemilumi-
nescent substrate (SuperSignal West Pico; Pierce, Rockford,
IL). To prepare a control for protein loading, bound antibod-
ies were stripped from the PVDF membrane by incubation in
buffer containing 2% SDS, 62.5 mM Tris-HCl (pH 6.8) and
100 mM 2-mercaptoethanol (all from Sigma) for 15 min at
room temperature. The membrane was reprobed with β-actin
mouse monoclonal antibody (Sigma) diluted at 1:10,000 in
5% non-fat dry milk in PBS followed by incubation in HRP-
conjugated donkey anti-mouse IgG diluted at 1:20,000 in 5%
non-fat dry milk in PBS. A positive control sample was pre-
pared from SW480 cells, a human colorectal adenocarcinoma
cell line (American Type Culture Collection, Manassas, VA).
Semi-quantitative analysis of protein expression was per-
formed by densitometry using NIH Image software (NIH Im-
age 1.34; National Institutes of Health, Bethesda, MD). Ex-
pression of PTP1B was normalized relative to that of β-actin.
Duplicate immunoblots were prepared and each experiment
was repeated three times.
Immunocytochemical localization of PTP1B:  Rat cor-
neas were washed in PBS and then fixed with 100% methanol
for 10 min at -20 °C. All subsequent steps were performed at
room temperature. Corneas were washed 3 times in PBS for
10 min each, then permeabilized for 10 min with 1% Triton
X-100 in PBS, and washed again 3 times in PBS for 10 min
each. Nonspecific binding was blocked using 4% bovine se-
rum albumin (BSA; Fisher, Pittsburgh, PA) in PBS for 10 min.
Corneas were incubated for 2 h in PTP1B mouse monoclonal
antibody diluted 1:50 in 4% BSA in PBS and at the same time
in β-catenin goat polyclonal antibody (Santa Cruz Biotech-
nology) diluted 1:100 in 4% BSA in PBS. Corneas were
washed 3 times in PBS for 10 min each and then incubated for
1 h with rhodamine red-X donkey anti-mouse IgG diluted
1:100 in 4% BSA in PBS for detection of PTP1B antibody
and FITC donkey anti-goat IgG diluted at 1:50 to detect β-
catenin antibody. Both secondary antibodies were obtained
from Jackson ImmunoResearch Laboratories. Negative con-
trols consisted of secondary antibody alone. After being washed
in PBS 3 times for 10 min each, corneas were placed endothe-
lial-side up on slides using mounting medium (Vector Labo-
ratories, Burlingame, CA). Digital images were obtained us-
ing a Leica TSC-SP2 confocal microscope (Bannockburn, IL).
A Z-series through the tissue was captured with a step size of
0.5 µm per image. Z-series images were collapsed onto a single
image plane by projecting the maximal pixel intensity of the
images.
Immunocytochemical localization of EGFR following
EGF stimulation:  Rat corneas were washed and incubated
for 0, 15, and 60 min in Medium 199, gentamicin, 0.1% FBS
plus 10 ng/ml epidermal growth factor (EGF; Upstate Bio-
technology, Charlottesville, VA). The corneas were then
washed in PBS and fixed with 100% methanol for 10 min at -
20 °C. All subsequent steps were performed at room tempera-
ture. Corneas were washed 3 times in PBS for 10 min each,
then permeabilized for 10 min with 1% Triton X-100 in PBS,
and washed again 3 times in PBS for 10 min each. Nonspe-
cific binding was blocked using 4% BSA in PBS for 10 min.
Corneas were incubated for 2 h in EGF receptor (EGFR) sheep
polyclonal antibody diluted 1:30 in 4% BSA in PBS or ZO-1
mouse monoclonal antibody (Zymed/Invitrogen) diluted 1:150
in 4% BSA in PBS. Corneas were washed 3 times in PBS for
10 min each and then incubated for 1 h with FITC donkey
anti-sheep IgG diluted at 1:50 for detection of EGFR or
rhodamine red-X donkey anti-mouse IgG diluted 1:200 in 4%
BSA in PBS for detection of ZO-1. Both secondary antibod-
ies were obtained from Jackson ImmunoResearch Laborato-
ries. Negative controls consisted of secondary antibody alone.
After being washed in PBS 3 times for 10 min each, corneas
were placed endothelial-side up on slides using mounting
medium (Vector Laboratories). Digital images were obtained
as described above.
Western blot analysis of effect of PTP1B inhibitor on
EGFR Tyr992 levels:  Confluent passage 1 rat corneal endot-
helial cells were trypsinized, seeded in 60 mm petri dishes at
a density required to yield 50% confluence, and incubated
overnight in the presence of 10% serum to permit cell attach-
ment. Cells were then serum-starved for 24 h in Medium 199
plus gentamicin. For initial testing of the EGFR Tyr992 time-
course, cells were incubated with EGF at a concentration of
25 ng/ml in Medium 199 and gentamicin without serum for 0,
10, 20, 30, 40, 50, or 60 min. These control experiments were
repeated 3 times. CinnGEL 2Me, a novel peptoid inhibitor of
PTP1B [38], was used to test the effect of PTP1B inhibition
on the time-course of EGFR Tyr992 phosphorylation.
CinnGEL 2Me was reconstituted in dimethyl sulphoxide
(DMSO: Sigma) as indicated by the manufacturer (BioMol
Research Laboratories, Plymouth Meeting, PA). Cells were
incubated in the presence of CinnGEL 2Me at a final concen-
tration of 1 mM or in an equal volume of DMSO in Medium
199 and gentamicin without serum for 1 h prior to the start of
the experiment. EGF was then added at a concentration of 25
ng/ml to the CinnGEL 2Me or DMSO-containing medium and
cells were incubated for 0, 2, 5, 15, 30, 60, or 120 min. At
each time-point, dishes were placed on ice and cells were
washed with ice-cold PBS. Protein extraction, gel electrophore-
sis, and protein transfer to PVDF membranes were performed
as described above. Nonspecific binding was blocked by in-
cubation of the membrane for 1 h at room temperature in 5%
non-fat dry milk and 0.1% Triton X-100 diluted in PBS. The
membrane was briefly washed with 0.1% Triton X-100 in PBS
787and then incubated overnight at 4 °C with EGFR Tyr992 rab-
bit polyclonal antibody (Cell Signaling Technology, Danvers,
MA) diluted at 1:500 in 5% BSA and 0.1% Triton X-100 in
PBS. Blots were then rinsed 2 times for 10 min each with PBS
containing 0.1% Triton X-100 and incubated 1 h at room tem-
perature with HRP-conjugated donkey anti-rabbit IgG (Jack-
son ImmunoResearch Laboratories) at a 1:2,000 dilution in
5% non-fat dry milk and 0.1% Triton X-100 diluted in PBS.
Membranes were washed 2 times with PBS containing 0.1%
Triton X-100 for 10 min and antibody binding was visualized
using a chemiluminescent substrate (SuperSignal West Femto;
Pierce). To prepare a control for protein loading, bound anti-
bodies were stripped as described above. The membrane was
re-probed with β-actin mouse monoclonal antibody (Sigma)
diluted at 1:10,000 in 5% non-fat dry milk in PBS followed
by incubation in HRP-conjugated donkey anti-mouse IgG di-
luted in 5% non-fat dry milk in PBS at 1:20,000. Quantifica-
tion of protein bands was performed by densitometry as de-
scribed above. β-Actin was used for normalization. Experi-
ments comparing CinnGEL 2Me and DMSO controls were
repeated 4 times. Averaged data is presented ± standard error
of the mean (SEM).
Analysis of PTP1B inhibitor on cell cycle entry:  Confluent
passage 1 rat corneal endothelial cells were trypsinized as
above and seeded into 4-well glass chamber slides (Lab-Tek
II, Nagle Nunc International, Rochester, NY) coated with FNC
Coating Mix (AthenaES, Baltimore, MD) to yield 50%
confluence. Cells were incubated in Medium 199, gentami-
cin, and 0.1% FBS overnight and then the medium was changed
to 0% FBS for 24 h. CinnGEL 2Me (1 mM final concentra-
tion) or DMSO was added to the medium for 1 h prior to the
start of the experiment. EGF was added to all wells at a final
concentration of 25 ng/ml and cells were incubated for 0, 6, or
18 h. At each time point, the slides were processed for immu-
nocytochemistry as follows: Cells were washed quickly 3 times
with PBS and then fixed with 100% methanol for 10 min at -
20 °C. All subsequent steps were performed at room tempera-
ture. Cells were washed 3 times in PBS for 10 min each and
then permeabilized for 10 min with 1% Triton X-100 in PBS.
Cells were washed 3 times in PBS for 10 min each. Nonspe-
cific binding was blocked using 4% BSA in PBS. Cells were
incubated for 2 h in Ki67 mouse monoclonal antibody
(Novocastra, Newcastle upon Tyne, UK) diluted at 1:50 in
4% BSA in PBS. Cells were washed 3 times in PBS for 10
min each and then incubated for 1 h in FITC-conjugated don-
key anti-mouse IgG diluted at 1:50 in 4% BSA in PBS. The
cells were washed in PBS 3 times for 10 min each and pre-
pared in mounting medium containing propidium iodide (PI:
Vector Laboratories). Digital fluorescent images were obtained
using an Eclipse E800 Nikon Microscope with VFM Epi-Fluo-
rescence Attachment (Nikon, Inc., Melville, NY) equipped
with a Spot digital camera and Spot Advanced version 4.5 CE
software (Diagnostic Instruments, Sterling Heights, MI). Ki67
and PI-positive cells were counted from 3 different areas in
duplicate wells per experiment and the average percent of
Ki67-positive cells was calculated. Averaged data is presented
±SEM.
RESULTS
Expression of PTP1B in confluent and subconfluent cells:
Previous studies [34] provided immunocytochemical and west-
ern blot evidence that rat corneal endothelial cells express
PTP1B. The current studies confirmed and extended this find-
ing by comparing relative mRNA and protein expression for
PTP1B in confluent versus subconfluent rat corneal endothe-
lial cells. Cells were maintained in the presence of 10% FBS
prior to processing for RT-PCR and western blots. RT-PCR
revealed positive bands for PTP1B and G3PDH for both
confluent and subconfluent cells (Figure 1A,B). Controls con-
taining all reagents plus PTP1B primers, but without cDNA,
were negative. Samples containing total RNA rather than
cDNA yielded no positive bands, indicating lack of contami-
nation of the RNA samples with genomic DNA. Band density
for PTP1B was very similar in both confluent and subconfluent
cells. In this study, PCR was performed using two sets of primer
pairs based on methods recommended by the supplier. To con-
firm these results, PCR of the second set of primers was run
for 10, 20, and 26 cycles for both samples. Similar results
were obtained under all cycle conditions (data not shown) and
indicate that PTP1B mRNA is expressed at similar levels in
both confluent and subconfluent cells. Western blots (Figure
1C,D) showed a strong positive band for PTP1B in the posi-
tive control, as well as positive bands for both corneal endot-
helial samples. In contrast to the RT-PCR data, densitometric
analysis of the western blots indicates that PTP1B is expressed
at 3 fold higher levels in subconfluent versus confluent cells.
Experiments were performed 3 times and similar results were
obtained for both the RT-PCR and western blots in each ex-
periment.
PTP1B localization in endothelial cells of ex vivo rat cor-
neas:  Although previous studies [34] provided evidence that
PTP1B is expressed in rat corneal endothelial cells, they did
not clearly determine its subcellular location. Confocal im-
ages in Figure 2 show positive staining for PTP1B in a punc-
tate pattern suggestive of cytoplasmic vesicles. Comparison
of the PTP1B staining pattern with staining for β-catenin, a
protein associated with cell-cell adhesion junctions [39], indi-
cates that PTP1B is associated with vesicular structures im-
mediately subjacent to the plasma membrane. Tissue incubated
in secondary antibody alone was negative in all cases (data
not shown).
Localization of EGFR in rat corneal endothelial cells in
response to EGF stimulation:  Immunocytochemical local-
ization studies were conducted to determine the effect of EGF
treatment on the localization of EGFR. Ex vivo rat corneas
were incubated in the presence of EGF for 0, 15, and 60 min.
Corneas were fixed at each time point, immunostained for
EGFR, and analyzed by confocal microscopy. Representative
images are shown in Figure 3. In the absence of EGF (Figure
3A), endothelial cells exhibited intense staining for EGFR at
cell borders and diffuse punctate staining throughout the cell
interior. Within 15 min after exposure to EGF (Figure 3B),
there was a visible reduction in EGFR staining at lateral mem-
branes (although cell borders could still be seen in some ar-
eas) and the diffuse punctate cytoplasmic staining appeared
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788to increase. By 60 min after EGF addition (Figure 3C), little-
to-no staining for EGFR was visible at cell borders; however,
staining for ZO-1, a tight junction-associated protein [39] in
the same tissue (Figure 3D) indicated that cell-cell contacts
remained intact in the presence of EGF.
Time-course of EGFR Tyr992 phosphorylation:  Studies
were first conducted to determine the effect of EGF on the
time-course of phosphorylation of EGFR Tyr992. Serum-
starved subconfluent rat corneal endothelial cells were treated
with 25 ng/ml EGF in Medium 199 plus gentamicin. This con-
centration of EGF was chosen based on preliminary dose-re-
sponse studies (data not shown). Samples were then taken for
western blot analysis of phosphorylated Tyr992 at 0, 10, 20,
30, 40, 50, or 60 min following EGF addition and results are
shown in Figure 4. Figure 4A presents a representative west-
ern blot showing the time-course of EGFR Tyr992 phospho-
rylation following EGF stimulation. Densitometric analysis
of the blots (Figure 4B) indicates that phosphorylated Tyr992
levels peaked by 10 min following EGF addition and decreased
to basal levels by 30 min.
Effect of PTP1B inhibitor on time-course of EGFR Tyr992
phosphorylation:  Studies were then conducted to determine
the effect of CinnGEL 2Me, a peptoid inhibitor of PTP1B, on
the time-course of Tyr992 phosphorylation. CinnGEL 2Me is
the methyl ester of a tripeptide-substituted cinnamic acid that
exhibits significant inhibition of PTP1B activity [38]. The
supplier of CinnGEL 2Me states that the methyl ester permits
cell permeability and is hydrolyzed to active inhibitor by in-
tracellular esterases. For this study, subconfluent cultures of
rat corneal endothelial cells were serum-starved for 24 h and
then preincubated for 1 h in culture medium containing Me-
dium 199, gentamicin, and DMSO either with or without 1
mM CinnGEL 2Me. DMSO was used as a control for these
experiments, because the inhibitor was solubilized in this re-
agent. The concentration of CinnGEL 2Me was chosen fol-
lowing a preliminary dose-response study (data not shown).
After this 1 h incubation, cultures were treated with 25 ng/ml
EGF for 0, 2, 5, 15, 30, 60, or 120 min and samples were
taken for western blot analysis. Figure 5A presents represen-
tative results of the western blots and Figure 5B shows the
results of the densitometric analysis. Overall, the kinetics of
EGFR Tyr992 phosphorylation in cells maintained in control
medium containing DMSO were very similar to those de-
scribed above in which cells were maintained in medium with-
out DMSO. This indicates that DMSO did not affect the abil-
ity of the cells to respond to EGF stimulation. In the DMSO-
treated control cells, phosphorylated Tyr992 levels peaked 5
min after EGF addition, rapidly decreased to near-basal levels
by 30 min, and then gradually returned to basal levels by 120
min. In CinnGEL 2Me-treated cells, Tyr992 phosphorylation
peaked 2 min after EGF addition. Although the relative level
of phosphorylation decreased over time, it was consistently
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Figure 1. Representative results comparing PTP1B mRNA and protein expression in confluent and subconfluent rat corneal endothelial cells.
A: RT-PCR for PTP1B. At left are molecular weight markers in 100 bp increments with the brightest band at 600 bp. Lane 1: Control sample
containing all reagents, but without cDNA; Lane 2: cDNA extracted from confluent cells; Lane 3: cDNA extracted from subconfluent cells.
Position of 443 bp band for PTP1B is indicated. B: RT-PCR for G3PDH control. At left are molecular weight markers; Lane 4: Control sample
containing total RNA extracted from confluent cells; Lane 5: cDNA extracted from confluent cells; Lane 6: Control sample containing total
RNA extracted from subconfluent cells; Lane 7: cDNA extracted from subconfluent cells. Position of 452 bp G3PDH band is indicated. C:
Western blot for PTP1B (48 kDa) showing position of PTP1B in control SW480 cells and relative expression of PTP1B in subconfluent (SC)
and confluent (C) rat corneal endothelial cells. D: Same membrane as in (C) reprobed for β-actin to control for protein load.
789sustained at a level higher than that observed in controls until
the 60 min time-point. Thus, inhibition of PTP1B by CinnGEL
2Me resulted in a more rapid response to EGF stimulation
and an increased duration of EGFR Tyr992 phosphorylation.
Effect of PTP1B inhibitor on cell cycle entry:  Studies
were also conducted to determine the effect of PTP1B inhibi-
tor on EGF-stimulated cell cycle entry. For these studies,
subconfluent rat corneal endothelial cells were serum-starved,
pre-treated with or without 1 mM CinnGEL 2Me, and then
stimulated with 25 ng/ml EGF as previously. Cells were then
immunostained for Ki67, a marker of actively cycling cells
[35], at 0, 6, and 18 h after EGF addition. Cells positively
stained for Ki67 and total propidium iodide (PI)-stained nu-
clei were counted and the results compared. Figure 6A pre-
sents representative fluorescent images of Ki67- and PI-stained
cells at 6 and 18 h after EGF treatment, while Figure 6B shows
the percent of Ki67-positive cells averaged from duplicate
samples in three separate experiments. As expected from the
normal time-course of cell cycle progression in rat corneal
endothelial cells [36], there were no Ki67-positive cells at the
0 h time-point (data not shown) and there was a low number
of Ki67-positive cells at the 6 h time-point under both treat-
ment conditions. By 18 h after EGF treatment, the average
number of Ki67-positive cells was increased at least 1.7 fold
in cultures treated with CinnGEL 2Me compared with cul-
tures incubated in control medium.
DISCUSSION
 This laboratory is the first to explore a role for protein ty-
rosine phosphatases in the regulation of growth factor signal-
ing in corneal endothelium from any species. In a previous
study [34] we used rat corneal endothelium to identify a sub-
set of PTPs expressed in these cells and to examine the effect
of SOV-induced PTP inhibition on cell cycle entry. PTP1B
was among the PTPs identified in that study. PTP1B is widely
expressed, but its specific function(s) within individual cell
types is still being investigated [14]. PTP1B is clearly involved
in the regulation of signal transduction and has been found to
play an important role in diabetes, obesity, the cell cycle, and
cancer [40]. Since PTP1B is known to regulate EGFR signal-
ing and corneal endothelial cells express these receptors, it is
important to obtain a better understanding of the role of this
PTP in EGF-induced cell cycle traverse. The current studies
were conducted in rat corneal endothelial cells, because the
initial studies were conducted in this species and it was im-
portant to obtain a base of information in rat that could even-
tually be applied to studies of PTP1B in human corneal en-
dothelial cells. The goal of these studies was to determine
whether PTP1B plays a role in regulating EGF-induced Tyr992
phosphorylation of EGFR and cell cycle entry in rat corneal
endothelial cells.
The current studies confirmed and extended the finding
that PTP1B is expressed in rat corneal endothelial cells. PTP1B
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Figure 2. Representative fluorescent confocal images showing immunostaining for PTP1B and β-catenin in corneal endothelial cells of ex
vivo rat corneas.  PTP1B (red) localization is compared with that of β-catenin (green), a protein closely associated with cell-cell adhesion
junctions. The staining pattern of PTP1B strongly suggests that PTP1B is associated with vesicular structures subjacent to the plasma mem-
brane. The higher magnification image in (B) is included to more clearly demonstrate this localization pattern. The final magnification in A
was 2100X and in B was 3120X.
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Figure 3. Fluorescent confocal images of EGFR localization in cor-
neal endothelial cells of ex vivo rat corneas following EGF stimula-
tion.  In the absence of EGF, EGFR is located mainly at cell borders
(arrow), although some cytoplasmic punctate staining is visible (A).
After EGF stimulation for 15 min (B), EGFR staining is greatly re-
duced at cell borders (arrow). After 60 min (C), little-to-no EGFR is
visible at cell borders; however, ZO-1 staining of the same tissue (D)
indicates that cell borders remain intact. No staining is observed in
the endothelium of ex vivo corneas incubated in secondary antibody
alone (E). Note that small dots of intense stain can be observed scat-
tered in the cytoplasm of cells in (A-C). The specific nature of this
staining is unclear, since all antibodies were centrifuged at high speed
prior to dilution to prevent nonspecific antibody deposition. Final
magnification: 1000X.
791protein levels were found to be substantially higher in
subconfluent cells compared with confluent cells, while PTP1B
mRNA levels were similar, strongly suggesting that PTP1B
expression is regulated mainly at the protein level in these
cells. This finding is interesting, because subconfluent cells
were used in studies testing the effect of the PTP1B inhibitor.
Protein tyrosine phosphorylation is normally balanced by de-
phosphorylation, suggesting that the relative expression of
PTPs may be dependent on overall tyrosine phosphorylation
activity. In fact, several studies have demonstrated that ex-
pression of PTP1B is increased upon neoplastic transforma-
tion [41,42], as well as in cancer [43,44]. Overall, our finding
of increased PTP1B protein levels in subconfluent cells ap-
pears consistent with increased proliferative activity. The spe-
cific mechanism by which PTP1B protein levels are regulated
in corneal endothelial cells remains to be determined. PTP1B
has also been shown to regulate both cadherin- [45] and
integrin-based adhesion in some cells [46,47]. The relative
difference in PTP1B protein levels in confluent versus
subconfluent cells may also reflect these functions of PTP1B
in corneal endothelial cells, but this remains to be established.
The PTP1B staining pattern in the endothelium suggests
it is associated with submembranous vesicles; however, the
current studies did not test whether PTP1B is specifically as-
sociated with the endoplasmic reticulum as has been reported
in other cell types [24]. The fact that EGFR is internalized in
response to EGF stimulation suggests that it could interact
with and be regulated by PTP1B. Indeed, the similarity in the
kinetics of EGFR internalization and the kinetics of Tyr992
phosphorylation supports this idea. The kinetics of EGFR
Tyr992 phosphorylation in cells incubated in culture medium
containing DMSO were very similar to those of cells incu-
bated in medium without DMSO, indicating that DMSO did
not significantly affect EGF-induced signaling, at least under
these experimental conditions. The finding that inhibition of
PTP1B activity by CinnGEL 2Me results in sustained EGFR
Tyr992 phosphorylation compared with controls is similar to
that of Haj, et al. [28], who found that fibroblasts isolated from
PTP1B-/- mice exhibited increased and sustained phosphory-
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Figure 4. Time-course of EGFR Tyr992 phosphorylation.
Subconfluent rat corneal endothelial cells were serum-starved and
then treated with 25 ng/ml EGF in Medium 199 plus gentamicin.
Samples were taken at various times for western blot analysis. A:
Representative western blot showing the time-course of EGFR Tyr992
phosphorylation. Phosphorylated EGFR Tyr992 yields a 175 kDa
band. β-Actin (42 kDa) was used for a loading control. B: Graph
showing the average level of phosphorylated EGFR Tyr992 in dupli-
cate gels from three separate experiments. β-Actin was used for nor-
malization. Bars represent SEM.
 Figure 5. Effect of the PTP1B inhibitor, CinnGEL 2Me, on the time-
course of EGFR Tyr992 phosphorylation. Serum-starved,
subconfluent rat corneal endothelial cells were pre-incubated for 1 h
in Medium 199, gentamicin, and DMSO(-) or supplemented with 1
mM CinnGel 2Me(+). EGF (25 ng/ml) was then added and samples
were taken for western blot analysis at various times following EGF
addition. Representative western blot in (A) shows phosphorylated
Tyr992 at 175 kDa. Densitometric analysis was conducted using β-
actin for normalization. The graph in (B) shows average levels of
phosphorylated Tyr992. Results are the average of duplicate gels from
four separate experiments. Bars represent SEM.
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Figure 6. Effect of CinnGEL 2Me inhibition
of PTP1B on cell cycle entry. Serum-starved
subconfluent rat corneal endothelial cells were
preincubated for 1 h in medium containing
either DMSO(-) or 1 mM CinnGel 2Me in
DMSO(+) followed by addition of 25 ng/ml
EGF for 6 or 18 h. A: Cultures were
immunostained for Ki67 (green), a marker of
proliferating cells, and counterstained with
propidium iodide (PI) to reveal all nuclei (red).
Magnification: 400X. B: Bar graph shows the
average number of Ki67-positive cells at each
time-point in duplicate samples from three
separate experiments. Bars represent SEM and
the asterisk indicates a 1.7 fold increase over
control.
793lation of EGFR, as well as of the receptor for PDGF. Together,
results strongly suggest that PTP1B negatively regulates EGF-
induced receptor signaling in rat corneal endothelial cells.
Previous studies found that treatment of rat corneal en-
dothelial cells with the general phosphatase inhibitor, SOV,
increased the number of Ki67-positive cells over controls, in-
dicating that phosphatase inhibition promoted cell cycle en-
try. These results were similar to those reported by Suzuki, et
al. [48], who showed that SOV treatment promoted cell cycle
entry in cultured vascular endothelial cells. The current study
extends this finding by demonstrating that treatment of
subconfluent rat corneal endothelial cells with CinnGEL 2Me
increased the number of Ki67-positive cells, thereby impli-
cating PTP1B in the negative regulation of EGF-induced cell
cycle entry. The current studies did not explore the effect of
CinnGEL 2Me on the extent of cell cycle traverse. Positive
staining for Ki67 is first upregulated in mid-G1-phase of the
cell cycle [49,50]. As such, the observed increase in the num-
ber of Ki67-positive cells in CinnGEL 2Me treated cultures
suggests that more cells had at least begun to enter the cell
cycle. In the previous study of rat corneal endothelial cells
treated with SOV, it appeared that inhibition of phosphatases
was not sufficient to move cells from mid-G1 through S-phase
of the cycle, since there was no increase found in the number
of BrdU-stained cells. It is possible that inhibition of PTP1B
is sufficient to promote changes leading to the initial stages of
cell cycle entry, but that other signaling mechanisms compen-
sate for the lack of PTP1B activity, resulting in the inability of
cells to further traverse the cycle. This possibility was sug-
gested by Haj et al. [28] who observed an increase in EGFR
phosphorylation in PTP1B-/- mice, but detected little-to-no
increase in the activity of downstream signals, suggesting the
existence of compensatory mechanisms to prevent uncon-
trolled growth factor receptor activation. Further study will
be needed to more specifically identify the changes induced
by PTP1B inhibition that promote cell cycle entry. In addi-
tion, careful studies are needed to identify the specific down-
stream signaling cascades affected by PTP1B activity. It is
assumed that PLC-γ and the GAP-MAP kinase cascades will
be affected, since these proteins appear to compete for PTP1B
binding for phosphotyrosines on EGFR in other cell types. It
should also be mentioned that EGF is not the only growth
factor known to stimulate proliferation in corneal endothelial
cells. For example, significant information has been obtained
in rabbit corneal endothelial cells regarding cell cycle regula-
tion by fibroblast growth factor-2 (FGF-2) [51,52]. It would
be interesting to determine whether PTP1B might help regu-
late FGF-2 signaling in these cells, as has been found in cul-
tured smooth muscle cells [27].
In summary, results strongly suggest that PTP1B plays a
role in the negative regulation of EGFR signaling in rat cor-
neal endothelial cells, at least at the level of Tyr992 phospho-
rylation, and that inhibition of PTP1B activity increases both
the duration of EGFR autophosphorylation and the relative
number of cells entering the cell cycle. With this base of in-
formation, studies can now be conducted to explore the role
of PTP1B in regulation of EGFR signaling in human corneal
endothelium.
ACKNOWLEDGEMENTS
 The authors thank Ms. Rebecca Ickes for her excellent tech-
nical assistance in conducting the studies of EGFR internal-
ization following EGF stimulation. Supported by NEI R01
EY05767 to NCJ. An abstract reporting preliminary results of
this study has been presented: Harris DL, Joyce NC. Effects
of PTP1B Inhibition on Rat Corneal Endothelial Cells. ARVO
Annual Meeting; 2006 April 30-May 4; Fort Lauderdale (FL).
REFERENCES
 1. Joyce NC. Proliferative capacity of the corneal endothelium. Prog
Retin Eye Res 2003; 22:359-89.
2. Joyce NC. Cell cycle status in human corneal endothelium. Exp
Eye Res 2005; 81:629-38.
3. Jumblatt MM, Matkin ED, Neufeld AH. Pharmacological regula-
tion of morphology and mitosis in cultured rabbit corneal en-
dothelium. Invest Ophthalmol Vis Sci 1988; 29:586-93.
4. Savion N, Isaacs JD, Shuman MA, Gospodarowicz D. Prolifera-
tion and differentiation of bovine corneal endothelial cells in
culture. Metab Pediatr Syst Ophthalmol 1982; 6:305-20.
5. Woost PG, Jumblatt MM, Eiferman RA, Schultz GS. Growth fac-
tors and corneal endothelial cells: II. Characterization of epi-
dermal growth factor receptor from bovine corneal endothelial
cells. Cornea 1992; 11:11-9.
6. Soltau JB, McLaughlin BJ. Effects of growth factors on wound
healing in serum-deprived kitten corneal endothelial cell cul-
tures. Cornea 1993; 12:208-15.
7. Raphael B, Kerr NC, Shimizu RW, Lass JH, Crouthamel KC, Glaser
SR, Stern GA, McLaughlin BJ, Musch DC, Duzman E, Conway
J, Schultz GS. Enhanced healing of cat corneal endothelial
wounds by epidermal growth factor. Invest Ophthalmol Vis Sci
1993; 34:2305-12.
8. Fabricant R, Salisbury JD, Berkowitz RA, Kaufman HE. Regen-
erative effects of epidermal growth factor after penetrating
keratoplasty in primates. Arch Ophthalmol 1982; 100:994-5.
9. Nayak SK, Samples JR, °JK, Binder PS. Growth characteristics of
primate (baboon) corneal endothelium in vitro. Invest
Ophthalmol Vis Sci 1986; 27:607-11.
10. Samples JR, Binder PS, Nayak SK. Propagation of human cor-
neal endothelium in vitro effect of growth factors. Exp Eye Res
1991; 52:121-8.
11. Blake DA, Yu H, Young DL, Caldwell DR. Matrix stimulates the
proliferation of human corneal endothelial cells in culture. In-
vest Ophthalmol Vis Sci 1997; 38:1119-29.
12. Zhu C, Joyce NC. Proliferative response of corneal endothelial
cells from young and older donors. Invest Ophthalmol Vis Sci
2004; 45:1743-51.
13. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31:637-43.
14. Tonks NK. PTP1B: from the sidelines to the front lines! FEBS
Lett 2003; 546:140-8.
15. Milarski KL, Zhu G, Pearl CG, McNamara DJ, Dobrusin EM,
MacLean D, Thieme-Sefler A, Zhang ZY, Sawyer T, Decker SJ,
Dixon JE, Saltiel AR. Sequence specificity in recognition of the
epidermal growth factor receptor by protein tyrosine phosphatase
1B. J Biol Chem 1993; 268:23634-9.
16. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis
and oncogenesis: signal diversification through combinatorial
ligand-receptor interactions. FEBS Lett 1997; 410:83-6.
©2007 Molecular Vision Molecular Vision 2007; 13:785-96 <http://www.molvis.org/molvis/v13/a86/>
79417. Raab G, Klagsbrun M. Heparin-binding EGF-like growth factor.
Biochim Biophys Acta 1997; 1333:F179-99.
18. Marshall CJ. Specificity of receptor tyrosine kinase signaling:
transient versus sustained extracellular signal-regulated kinase
activation. Cell 1995; 80:179-85.
19. Baass PC, Di Guglielmo GM, Authier F, Posner BI, Bergeron JJ.
Compartmentalized signal transduction by receptor tyrosine ki-
nases. Trends Cell Biol 1995; 5:465-70.
20. Miaczynska M, Pelkmans L, Zerial M. Not just a sink: endosomes
in control of signal transduction. Curr Opin Cell Biol 2004;
16:400-6.
21. Zhang ZY, Zhou B, Xie L. Modulation of protein kinase signal-
ing by protein phosphatases and inhibitors. Pharmacol Ther
2002; 93:307-17.
22. Chernoff J, Schievella AR, Jost CA, Erikson RL, Neel BG. Clon-
ing of a cDNA for a major human protein-tyrosine-phosphatase.
Proc Natl Acad Sci U S A 1990; 87:2735-9.
23. Liu F, Chernoff J. Protein tyrosine phosphatase 1B interacts with
and is tyrosine phosphorylated by the epidermal growth factor
receptor. Biochem J 1997; 327:139-45.
24. Frangioni JV, Beahm PH, Shifrin V, Jost CA, Neel BG. The
nontransmembrane tyrosine phosphatase PTP-1B localizes to
the endoplasmic reticulum via its 35 amino acid C-terminal se-
quence. Cell 1992; 68:545-60.
25. Haj FG, Verveer PJ, Squire A, Neel BG, Bastiaens PI. Imaging
sites of receptor dephosphorylation by PTP1B on the surface of
the endoplasmic reticulum. Science 2002; 295:1708-11.
26. Yudushkin IA, Schleifenbaum A, Kinkhabwala A, Neel BG,
Schultz C, Bastiaens PI. Live-cell imaging of enzyme-substrate
interaction reveals spatial regulation of PTP1B. Science 2007;
315:115-9.
27. Chang Y, Ceacareanu B, Zhuang D, Zhang C, Pu Q, Ceacareanu
AC, Hassid A. Counter-regulatory function of protein tyrosine
phosphatase 1B in platelet-derived growth factor- or fibroblast
growth factor-induced motility and proliferation of cultured
smooth muscle cells and in neointima formation. Arterioscler
Thromb Vasc Biol 2006; 26:501-7.
28. Haj FG, Markova B, Klaman LD, Bohmer FD, Neel BG. Regula-
tion of receptor tyrosine kinase signaling by protein tyrosine
phosphatase-1B. J Biol Chem 2003; 278:739-44.
29. Goldstein BJ, Ahmad F, Ding W, Li PM, Zhang WR. Regulation
of the insulin signalling pathway by cellular protein-tyrosine
phosphatases. Mol Cell Biochem 1998; 182:91-9.
30. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, Haj F,
Wang Y, Minokoshi Y, Kim YB, Elmquist JK, Tartaglia LA,
Kahn BB, Neel BG. PTP1B regulates leptin signal transduction
in vivo. Dev Cell 2002; 2:489-95.
31. Cheng A, Uetani N, Simoncic PD, Chaubey VP, Lee-Loy A,
McGlade CJ, Kennedy BP, Tremblay ML. Attenuation of leptin
action and regulation of obesity by protein tyrosine phosphatase
1B. Dev Cell 2002; 2:497-503.
32. Guo XL, Shen K, Wang F, Lawrence DS, Zhang ZY. Probing the
molecular basis for potent and selective protein-tyrosine phos-
phatase 1B inhibition. J Biol Chem 2002; 277:41014-22.
33. Zhang ZY, Lee SY. PTP1B inhibitors as potential therapeutics in
the treatment of type 2 diabetes and obesity. Expert Opin Investig
Drugs 2003; 12:223-33.
34. Chen WL, Harris DL, Joyce NC. Effects of SOV-induced phos-
phatase inhibition and expression of protein tyrosine phos-
phatases in rat corneal endothelial cells. Exp Eye Res 2005;
81:570-80.
35. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach
C, Stahmer I, Kloth S, Brandt E, Flad HD. Immunobiochemical
and molecular biologic characterization of the cell prolifera-
tion-associated nuclear antigen that is defined by monoclonal
antibody Ki-67. Am J Pathol 1991; 138:867-73.
36. Chen KH, Harris DL, Joyce NC. TGF-beta2 in aqueous humor
suppresses S-phase entry in cultured corneal endothelial cells.
Invest Ophthalmol Vis Sci 1999; 40:2513-9.
37. Erlich HA, Gelfand D, Sninsky JJ. Recent advances in the poly-
merase chain reaction. Science 1991; 252:1643-51.
38. Moran EJ, Sarshar S, Cargill JF, Shahbaz MM, Lio A, et al.
Radiofrequency tag encoded combinatorial library method for
the discovery of tripeptide-substituted cinnamic acid inhibitors
of the protein tyrosine phosphatase PTP1B. J Am Chem Soc
1995; 117:10787-10788.
39. Petroll WM, Hsu JK, Bean J, Cavanagh HD, Jester JV. The spa-
tial organization of apical junctional complex-associated pro-
teins in feline and human corneal endothelium. Curr Eye Res
1999; 18:10-9.
40. Dube N, Tremblay ML. Involvement of the small protein tyrosine
phosphatases TC-PTP and PTP1B in signal transduction and
diseases: from diabetes, obesity to cell cycle, and cancer.
Biochim Biophys Acta 2005; 1754:108-17.
41. Zhai YF, Beittenmiller H, Wang B, Gould MN, Oakley C,
Esselman WJ, Welsch CW. Increased expression of specific pro-
tein tyrosine phosphatases in human breast epithelial cells
neoplastically transformed by the neu oncogene. Cancer Res
1993; 53:2272-8.
42. LaMontagne KR Jr, Hannon G, Tonks NK. Protein tyrosine phos-
phatase PTP1B suppresses p210 bcr-abl-induced transforma-
tion of rat-1 fibroblasts and promotes differentiation of K562
cells. Proc Natl Acad Sci U S A 1998; 95:14094-9.
43. Wiener JR, Kerns BJ, Harvey EL, Conaway MR, Iglehart JD,
Berchuck A, Bast RC Jr. Overexpression of the protein tyrosine
phosphatase PTP1B in human breast cancer: association with
p185c-erbB-2 protein expression. J Natl Cancer Inst 1994;
86:372-8.
44. Bjorge JD, Pang A, Fujita DJ. Identification of protein-tyrosine
phosphatase 1B as the major tyrosine phosphatase activity ca-
pable of dephosphorylating and activating c-Src in several hu-
man breast cancer cell lines. J Biol Chem 2000; 275:41439-46.
45. Balsamo J, Arregui C, Leung T, Lilien J. The nonreceptor protein
tyrosine phosphatase PTP1B binds to the cytoplasmic domain
of N-cadherin and regulates the cadherin-actin linkage. J Cell
Biol 1998; 143:523-32.
46. Arregui CO, Balsamo J, Lilien J. Impaired integrin-mediated
adhesion and signaling in fibroblasts expressing a dominant-
negative mutant PTP1B. J Cell Biol 1998; 143:861-73. Erratum
in: J Cell Biol 1998; 143:1761.
47. Liang F, Lee SY, Liang J, Lawrence DS, Zhang ZY. The role of
protein-tyrosine phosphatase 1B in integrin signaling. J Biol
Chem 2005; 280:24857-63.
48. Suzuki E, Nagata D, Yoshizumi M, Kakoki M, Goto A, Omata
M, Hirata Y. Reentry into the cell cycle of contact-inhibited vas-
cular endothelial cells by a phosphatase inhibitor. Possible in-
volvement of extracellular signal-regulated kinase and
phosphatidylinositol 3-kinase. J Biol Chem 2000; 275:3637-44.
49. Kill IR. Localisation of the Ki-67 antigen within the nucleolus.
Evidence for a fibrillarin-deficient region of the dense fibrillar
component. J Cell Sci 1996; 109:1253-63.
50. Starborg M, Gell K, Brundell E, Hoog C. The murine Ki-67 cell
proliferation antigen accumulates in the nucleolar and hetero-
chromatic regions of interphase cells and at the periphery of the
mitotic chromosomes in a process essential for cell cycle pro-
gression. J Cell Sci 1996; 109:143-53.
©2007 Molecular Vision Molecular Vision 2007; 13:785-96 <http://www.molvis.org/molvis/v13/a86/>
795©2007 Molecular Vision Molecular Vision 2007; 13:785-96 <http://www.molvis.org/molvis/v13/a86/>
51. Kay EP, Gu X, Smith RE. Corneal endothelial modulation: bFGF
as direct mediator and corneal endothelium modulation factor
as inducer. Invest Ophthalmol Vis Sci 1994; 35:2427-35.
52. Gu X, Seong GJ, Lee YG, Kay EP. Fibroblast growth factor 2
uses distinct signaling pathways for cell proliferation and cell
shape changes in corneal endothelial cells. Invest Ophthalmol
Vis Sci 1996; 37:2326-34.
796
The print version of this article was created on 24 May 2007. This reflects all typographical corrections and errata to the article through that
date. Details of any changes may be found in the online version of the article. α